Everest Medicines Partner Calliditas Publish P-III (NeflgArd) Trial Results of Nefecon for Primary IgA Nephropathy in The Lancet
Shots:
- The P-III trial evaluates Nefecon in adults with primary IgAN. The trial met its 1EPs i.e., clinical benefit in eGFR over 2yr. period of 9mos. with Nefecon & 15mos. follow-up of the drug, decline in eGFR after 2yr. (6.11 vs 12.0mL/min/1.73 m2), a significant kidney protective effect over PBO
- Reduction in UPCR reflecting a long-lasting treatment effect during 15mos. follow-up period. Patients maintained a ≥30% proteinuria reduction from the end of the 9mos. through the entire follow-up period, reduction in UPCR (~50%) at 12mos., treatment discontinuation due to TEAEs (<10%), objective measures of mean weight & blood pressure showed non-clinically relevant changes
- Nefecon was approved & marketed under the brand name TARPEYO in the US & Kinpeygo in the EU & UK under accelerated & conditional approval
Ref: PRNewswire | Image: Everest medicines
Related News:- Everest Medicines Reports the Commercial Availability of Xerava (eravacycline) in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
